This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke Clinic

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2014 by Dr. Yair Lampl, Wolfson Medical Center.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Dr. Yair Lampl, Wolfson Medical Center
ClinicalTrials.gov Identifier:
NCT01109875
First received: April 22, 2010
Last updated: June 11, 2014
Last verified: June 2014
April 22, 2010
June 11, 2014
May 2010
December 2014   (Final data collection date for primary outcome measure)
positive screening of fabry disease [ Time Frame: past 5 years ]
Same as current
Complete list of historical versions of study NCT01109875 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke Clinic
Not Provided
The purpose of this study is to determine the incidence of Fabry Disease in young stroke patients in an Israeli stroke clinic.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Fabry Disease in the Young Stroke
Other: blood test
Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
1000
Not Provided
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

diagnosis of stoke or TIA Time period within last 5 years -

Exclusion Criteria:

Known diagnosis of stroke or index event due to trauma

Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT01109875
1
Not Provided
Not Provided
Not Provided
Dr. Yair Lampl, Wolfson Medical Center
Wolfson Medical Center
Not Provided
Not Provided
Wolfson Medical Center
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP